(Q46698294)

English

Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

0 references

author name string

Michael A Morgan

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

Tarkan Sebil

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

Erdem Aydilek

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

Dietrich Peest

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

Arnold Ganser

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

Christoph W M Reuter

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

130

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

912-925

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

The Ras family of GTPases in cancer cell invasion.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Isoprenoids influence expression of Ras and Ras-related proteins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Molecular aspects of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Actin' up: RhoB in cancer and apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Cell migration: Rho GTPases lead the way

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Isoprenylation of RhoB is necessary for its degradation. A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Inhibition of cdk2 activating phosphorylation by mevastatin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05696.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2005.05696.X

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16156861

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46698294&oldid=2127303206"